ArticleClinical epigenetics2025
Investigating the pathogenesis of urolithiasis through gut microbiome, plasma metabolome and inflammatory proteome: a mediation Mendelian randomization study.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetically Predicted 12,13-DiHOME Mediates the Association between TNF-Related Apoptosis-Inducing Ligand and Immune Thrombocytopenia.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUrolithiasis is a multifactorial systemic metabolic disease influenced by genetic, environmental, and dietary factors. Although previous observational studies have established strong links between the gut microbiome, plasma metabolome, inflammatory proteome, and urolithiasis, may be influenced by various confounding factors. This study aims to elucidate the causal relationships between gut microbiota (GM) and urolithiasis, and to investigate whether plasma metabolites and inflammatory proteins mediate this interaction.
methodsWe utilized publicly available dataset from genome-wide association studies (GWAS) to obtain data on GM, plasma metabolites, inflammatory proteins and urolithiasis. To elucidate the causal relationship between GM and urolithiasis, we conducted bidirectional Mendelian randomization (MR) analyses. Additionally, a two-step MR approach was applied to investigate whether GM contributes to the development of urolithiasis via plasma metabolites and inflammatory proteins, quantifying the mediation effect. Inverse variance weighting (IVW) was the primary method, with Bayesian weighted Mendelian randomization (BWMR), MR-Egger, and weighted median (WM) analyses used to ensure the robustness of our findings. Tests for horizontal pleiotropy and heterogeneity were conducted to confirm the reliability of the results. OUTCOME: MR analyses identified causal relationships between seven GM taxa and six metabolic pathways with urolithiasis, while urolithiasis induced changes in 13 GM taxa and five metabolic pathways. Additionally, 43 plasma metabolites (27 identified, 8 unidentified, and 8 metabolite ratios) and six inflammatory proteins were identified as potential mediators in the GM-urolithiasis connection. Through two-step mediation analysis, 13 causal pathways were identified. After excluding metabolic pathways and unidentified metabolites, we determined that galactonate and LAP-TGF-β1 mediate the relationship between Bacteroides faecis, Alistipes finegoldii, and urolithiasis, with mediation proportions of 16.99% (P = 0.0371) and 9.61% (P = 0.0469), respectively.
conclusionThe present MR analysis provides evidence supporting causal relationships between specific GM taxa and urolithiasis, with plasma metabolites and inflammatory proteins emerging as potential mediators.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.